VASCULAR SOLUTIONS D-STAT FLOWABLE HEMOSTAT

Device, Hemostasis, Vascular

FDA Premarket Approval P990037 S024

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for a new indication for use for the d-stat flowable hemostat. The device is indicated for use in high-risk anti-coagulated patients undergoing implantation of a pulse generator (e. G. , pacemaker or icd) to reduce the frequency of clinically relevant hematoma formation in the prepectoral pocket. D-stat flowable is indicated for use in high-risk anti-coagulated patients undergoing implantation of a pulse generator (e. G. , pacemaker or icd to reduce the frequency of clinically relevant hematoma formation in the prepectoral pocket. High-risk patients are defined as those whose anti-coagulation regimens will resume within 24 hours of implant. Clinically relevant hematomas are defined as those that result in an alteration in the standard of care resultant of hematoma formation including alteration (i. E. Suspension or discontinuation) of the anticoagulant therapy regimen (heparin, lmwh, warfarin, or clopidogrel), application of a compression bandage and evacuation of the hematoma.

DeviceVASCULAR SOLUTIONS D-STAT FLOWABLE HEMOSTAT
Classification NameDevice, Hemostasis, Vascular
Generic NameDevice, Hemostasis, Vascular
ApplicantVascular Solutions, Inc.
Date Received2006-06-22
Decision Date2006-12-22
Notice Date2007-05-11
PMAP990037
SupplementS024
Product CodeMGB
Docket Number07M-0188
Advisory CommitteeCardiovascular
Supplement TypePanel Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address Vascular Solutions, Inc. 6464 Sycamore Court North minneapolis, MN 55369
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P990037Original Filing
S036 2022-08-08 Normal 180 Day Track
S035 2021-06-14 30-day Notice
S034 2016-09-09 30-day Notice
S033
S032 2016-01-29 Special (immediate Track)
S031 2010-07-30 Normal 180 Day Track No User Fee
S030 2010-04-09 30-day Notice
S029 2009-11-04 30-day Notice
S028 2008-10-21 Real-time Process
S027
S026 2008-07-11 30-day Notice
S025 2007-06-14 Special (immediate Track)
S024 2006-06-22 Panel Track
S023 2005-08-05 Special (immediate Track)
S022 2004-06-15 Normal 180 Day Track No User Fee
S021 2004-06-15 Real-time Process
S020 2003-06-18 30-day Notice
S019 2003-05-16 Real-time Process
S018 2003-04-30 Normal 180 Day Track No User Fee
S017
S016
S015 2003-03-11 Real-time Process
S014 2003-02-24 Special (immediate Track)
S013 2003-01-23 30-day Notice
S012 2003-01-17 Real-time Process
S011 2002-08-26 30-day Notice
S010 2002-02-27 Normal 180 Day Track
S009 2002-03-15 Real-time Process
S008 2001-12-11 Normal 180 Day Track
S007 2001-11-28 Special (immediate Track)
S006 2001-05-21 Special (immediate Track)
S005 2001-05-01 Normal 180 Day Track
S004
S003 2001-02-07 Real-time Process
S002 2001-01-22 Real-time Process
S001 2000-10-04 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.